Key result
Pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter achieved entrance block in 100% of patients, with 1 primary adverse event within 7 days.
Why the study?
The study evaluated the safety and effectiveness of a compliant multi-electrode radiofrequency balloon catheter used with a multi-electrode diagnostic catheter for pulmonary vein isolation in symptomatic paroxysmal atrial fibrillation.
Does pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter safely achieve pulmonary vein isolation and prevent arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation?
Does pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter safely achieve pulmonary vein isolation and prevent arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation?
PVI with a novel multi-electrode radiofrequency balloon catheter is safe and effective for achieving PV isolation and improving quality of life in paroxysmal atrial fibrillation.
Supports safety and short-term efficacy of the novel balloon for PVI; leaves open confirmation in randomized trials.
AIMS: To evaluate the safety and effectiveness of a compliant multi-electrode radiofrequency balloon catheter (RFB) used with a multi-electrode diagnostic catheter for pulmonary vein isolation (PVI). METHODS AND RESULTS: This prospective, multicentre, single-arm study was conducted at six European sites and enrolled patients with symptomatic paroxysmal atrial fibrillation. The primary effectiveness endpoint was entrance block in treated pulmonary veins (PVs) after adenosine/isoproterenol challenge. The primary safety endpoint was the occurrence of primary adverse events (PAEs) within 7 days. Cerebral magnetic resonance imaging and neurological assessments were performed pre- and post-ablation in a subset of patients. Atrial arrhythmia recurrence was assessed over 12 months via transtelephonic and Holter monitoring. Quality of life was assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. Of 85 patients undergoing ablation per study protocol, PV entrance block was achieved in all (one PV required touch-up with a focal catheter). Acute reconnection of ≥1 PVs after adenosine/isoproterenol challenge was observed in 9.3% (30/324) of PVs ablated. Post-ablation, silent cerebral lesions were detected in 9.7% (3/31) of patients assessed, all of which was resolved at 1-month follow-up. One patient experienced a PAE (retroperitoneal bleed). Freedom from documented symptomatic and all arrhythmia was 72.2% and 65.8% at 12 months. Four patients (4.7%) underwent repeat ablation. Significant improvements in all AFEQT subscale scores were seen at 6 and 12 months. CONCLUSION: PVI with the novel RFB demonstrated favourable safety and effectiveness, with low repeat ablation rate and clinically meaningful improvement in quality of life. CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT03437733.
No takes yet. Share an insight, caveat, or question.
Schilling et al. (2020) studied symptomatic paroxysmal atrial fibrillation (n=85). multi-electrode radiofrequency balloon catheter was evaluated on entrance block in treated pulmonary veins (PVs) after adenosine/isoproterenol challenge. Pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter achieved entrance block in 100% of patients, with 1 primary adverse event within 7 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: